WA
NBIX icon

WFG Advisors’s Neurocrine Biosciences NBIX Stock Holding History

WFG Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50
Closed -$2K – 1647
2016
Q1 		$2K Hold
50
– – ﹤0.01% 1347
2015
Q4 		$3K Hold
50
– – ﹤0.01% 1308
2015
Q3 		$2K Sell
50
-100
-67% -$4.83K ﹤0.01% 1423
2015
Q2 		$7K Buy
+150
New +$6.36K ﹤0.01% 1274

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

WFG Advisors's NBIX Position: Q2 2016 in Review

WFG Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2016, closing a stake of 50 shares — an estimated $2K sold.

WFG Advisors first reported a position in NBIX in Q2 2015 and held it in 4 quarters. The position peaked at $7K in Q2 2015. 231 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

  • WFG Advisors reported no remaining Neurocrine Biosciences position as of Q2 2016 after selling out during the quarter.
  • WFG Advisors sold 50 Neurocrine Biosciences shares in Q2 2016, an estimated $2K.
  • WFG Advisors first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 4 quarters.
  • WFG Advisors's Neurocrine Biosciences position peaked at $7K in Q2 2015.
  • 231 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on WFG Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.